EP Patent

EP4321177A2 — Carbohydrate conjugates as delivery agents for oligonucleotides

Assigned to Alnylam Pharmaceuticals Inc · Expires 2024-02-14 · 2y expired

What this patent protects

The present invention relates to specific iRNA agents for use in medicine, as well as for use in methods of modulating the expression of a target gene in a hepatic cell.

USPTO Abstract

The present invention relates to specific iRNA agents for use in medicine, as well as for use in methods of modulating the expression of a target gene in a hepatic cell.

Drugs covered by this patent

vutrisiran-sodium (VUTRISIRAN SODIUM)

Patent Metadata

Patent number: EP4321177A2
Jurisdiction: EP
Classification: —
Expires: 2024-02-14
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.